Pain killers play a vital role in our lives. Through these therapeutics, we are alleviated from the discomfort of physical pain. In medicine, these therapeutics are one of the most highly used especially after any surgical procedures. There are several biopharmaceutical companies around the world who continue to invest in research and development for the best pain killers.
Pain Therapeutics, Inc. is just one of those biopharmaceutical companies which have a strong focus on creating these type of therapeutics. Compared to other companies though, the business has underscored their drug design as something that would reduce the potential risk of abuse of these medications. In addition to alleviating discomfort, some people are using pain killers as one of the most commonly abused drugs. The company intends to address this issue by creating therapeutics that are designed to reduce potential unintended use.
There are three pipeline candidates of the company, namely REMOXY (oxycodone), PTI-202 and PTI-721. REMOXY is the flagship product of the company. This therapeutic is used to manage moderate to severe pain and comes in an extended-release oral formulation. This oxycodone is in a form of a viscous liquid formulation and is designed to resist common forms of physical or chemical manipulation. This drug is categorized as an investigational drug candidate. The three drugs that are part of the portfolio of the company are all in the development stages and has not earned the approval of the Food and Drug Administration of the United States.
It is in Austin, Texas that the company holds its corporate office. It continues to compete against companies like Abbott Laboratories, Purdue Pharma, Pfizer, Teva Pharmaceuticals and several other biopharmaceutical companies. Pain Therapeutics, Inc. is a publicly traded company with common shares marketed on the NASDAQ, using the ticker symbol PTIE. The venture is listed as a component of the Wilshire 5000 Index.